On October 15, 2026, the U.S. Food and Drug Administration approved satralizumab-mwge (Enspryng), developed by Genentech, for adults with thyroid eye disease

From the articleFirst At-Home Thyroid Eye Disease Shot ApprovedAlso in Satralizumab Approved for Thyroid Eye Disease